Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Press releaseGlobeNewswire· November 27, 2025

CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi

View original at globenewswire.com

CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi Dublin, Nov…

Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

CD38 is an attractive target for antibody therapy because it is highly expressed on malignant plasma cells
100% confidence
CD38 is a clinically validated and commercially very successful target
100% confidence
Multiple Myeloma represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors
100% confidence
The patent holder of Darzalex expects that royalties from sales of DARZALEX will begin to decline materially in 2029 following expiration of U.S. patent rights on daratumumab
95% confidence

Cited in these Via News reports

China's Kelun-Biotech Fields 30+ Oncology Candidates in Global ADC Race Against Pfizer, Regeneron →